PIK3CA and breast cancer: The partial responses of the above targeted molecules lead to the search for new therapeutic targets for TNBC, which is made possible by the BC genomes sequencing, which identified over 2414 somatic mutations, such as p53, PIK3CA and PTEN, which seem to be clonally dominant compared to other genes [84].